Eli Lilly’s Taltz officially has a new arena to challenge Novartis’ Cosentyx.
As Merck stacks up indications for its cancer fighter Keytruda, it’s also adding treatment areas to its cancer awareness umbrella campaign.
Novartis heart failure med Entresto would have seen faster uptake if only it had been an oncology treatment, company executives figure.
Viagra Connect, the Pfizer OTC name for its blockbuster erectile dysfunction drug, has been approved for sale in the U.K.
Seniors and dementia patients in Japan can go out more safely thanks to a new tracking tool from Eisai.
GlaxoSmithKline’s ViiV only just won its first two-drug HIV approval, but it's already bolstering its trial program.
Gilead is introducing Sovaldi in China, where it faces mounting competitive pressure, at a steep discount.
InVentiv took a look what could impact pharma marketers in 2018, and it's identified half a dozen high-level trends for the year ahead.
Novartis has new data in hand that could help it snatch patients from GlaxoSmithKline with Advair rival Ultibro.
A new disease awareness campaign, sponsored by Acadia Pharmaceuticals, shines a light on the hallucinations and delusions that can affect half of people who…